ClinicalTrials.gg
CompletedNCT01657292Updated Sep 28, 2015Results posted

Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds

A Phase 3 interventional study of Oleogel-S10 ointment and Octenilin® wound gel in Burns, sponsored by Birken AG. Completed at 9 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-28.

Sponsored by Birken AG (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Burns with a site in Germany — 4 open to participants now, 4 under way, 1 of them phase 3. Burns · Germany.

Enrollment
13th of 21
61 · median 80
Started
2012
with 1 other
Phase 3
7 of 27
1 open now
Registered
9th of 27
by date
Lead sponsor
1 of 27
Birken AG

Among the 27 studies in Burns with a site in Germany, this one is the 13th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2012, is one of 7 in phase 3, and was the 9th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

4 of the 27 studies in Burns with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 85 Burns studies recruiting now, 38 (45%) set no upper age limit and 38 (45%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Burns with a site in Germany, or all of them as a file.
02

Study summary

The main goal of this phase III clinical trial is to show safety and efficacy of Oleogel-S10 in the acceleration of wound healing of grade 2a burn wounds.

Read the detailed description

Oleogel-S10 has shown efficacy and was well tolerated in previous clinical trials in patients with skin lesions. Especially the results in the split-thickness skin graft donor site, which is regarded as an excellent model for any kind of superficial wounds in human skin, suggest that Oleogel-S10 should be efficacious and safe in treatment of grade 2a burns.

The present Phase III clinical trial in grade 2a burns is initiated in order to measure the wound healing progress applying objective methods, i.e., the time to healing and the grade of epithelialization of the wound.

In this study, grade 2a burn wounds are separated into two halves: Following wound cleaning and disinfection, wounds are separated into two wound halves. Randomly assigned, one wound half receives Oleogel-S10 ointment, the other wound half standard of care treatment.

Wound healing progress is documented by photos which are assessed by expert reviewers blinded to the treatment of the wound halves.

03

Conditions studied

  • Burns

Browse trials for

Keywords

  • Wound healing
  • Burn wound
  • Superficial partial-thickness burn wound
  • Grade 2a burn wounds
  • Time to wound closure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients at least 18 years old who have provided written .
  • Presenting with acute grade 2a burn wounds (as graded by an expert surgeon assisted by LDI or a multispectral imaging system) within 48 hours after injury.
  • Burn wound caused by fire burn, heat burn or scalding.
  • Burn patients with grade 2a burn wounds between 80 cm2 and less than 25% of their TBSA (alternatively, 2 comparable wounds with size more than 40 cm2 each and less than 12.5% of the TBSA each are allowed).
  • Patient is able to understand the Informed Consent Form provided and is prepared to comply with all study requirements, including the following: Visiting the trial site for wound dressing changes at least every second day (if patient is not hospitalized) and photo documentation until full wound closure or until the Investigator decides to change medication and/or treatment after day 21 after start of treatment
  • Willing to perform all necessary wound dressing changes at the trial site. Also the patient needs to agree to return to site for 3 and 12 months follow-up visits.
  • Women of must apply highly effective method of (failure rate less than 1% per year when used consistently and correctly (e.g., implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner))

Exclusion criteria

Exclusion Criteria:

  • Suffering from chemical burns, or electrical burns or sunburns
  • Having already received treatment for their burn with silver sulfadiazine (obscures photographic wound evaluation).
  • Positive blood culture after the burn.
  • Diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety, tolerance or efficacy.
  • A skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial.
  • A history of to any of the drugs or surgical dressings to be used in this trial.
  • Known multiple allergic disorders.
  • Taking, or have taken, any drugs within 3 months prior to the screening visit.
  • Pregnant or breast feeding women are not allowed to participate in the study.
  • Inappropriate to participate in the study, for any reason, in the opinion of the Investigator.
  • Mental incapacity or language barriers precluding adequate understanding or co-operation or willingness to follow study procedures.
  • Previous participation in this study.
  • Employee at the investigational site, relative or spouse of the Investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Oleogel-S10 ointment

    Intra-individual comparison. Oleogel-S10 ointment is administered to one randomly assigned wound half.

    Drug: Oleogel-S10 ointment · Device: Octenilin® wound gel

  • Other
    Octenilin® wound gel

    Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.

    Drug: Oleogel-S10 ointment · Device: Octenilin® wound gel

Interventions

  • DrugOleogel-S10 ointment

    Drug pages: Episalvan · Birch triterpenes

    Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing

  • DeviceOctenilin® wound gel

    Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing

    Also known as: Contains Octenidine

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care

    Photo-based evaluation by independent experts blinded to the treatment regime.

    Time frame: 2 to 3 weeks

Secondary outcomes

  1. Intra-individual Difference in Time to Wound Closure Between Wound Halves, Either Treated With Oleogel-S10 or Treated With Standard of Care

    Time frame: 2 to 3 weeks

  2. Time From Study Start After Burn Accident Until Wound Closure is Achieved Separately for Wound Halves Treated With Oleogel-S10 vs. Standard of Care

    Time frame: 2 to 3 weeks

  3. Percentage of Patients With Wound Closure at Different Time Points

    Time frame: 2 to 3 weeks

  4. Percentage of Wound Epithelialization at Different Time Points as Assessed by the Investigator

    Time frame: 2 to 3 weeks

  5. Likert Scale Rating of Efficacy (Evaluated by Both the Investigators and Patients)

    By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to grade the efficacy of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale

    Time frame: 2 to 3 weeks

  6. Cosmetic Outcome After 3 and 12 Months After Burn Accident, in Relation to Texture, Redness, Growth of Hair and Pigmentation, Based on Blinded Photo Evaluation

    Time frame: 3 and 12 months

  7. Likert Scale Rating of Tolerance (Evaluated by Both the Investigators and Patients)

    By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to provide their opinion on the tolerance of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale

    Time frame: 2 to 3 weeks

  8. PK Data: Systemic Presence/Concentration of Betulin in Blood Plasma Samples

    Time frame: 2 to 3 weeks

  9. Microbial Colonization of the Wound Halves

    Time frame: 2 to 3 weeks

  10. Assessment of Adverse Events

    Time frame: 2 to 3 weeks

07

Results

Posted Sep 28, 2015

Participant flow

Study participants were enrolled from 31-Aug-2012 to 10-Jul-2013, in 10 clinical centres in 4 countries: Germany (4 centers), Uk (3 centers), Sweden (2 centers), and Switzerland (1 center).

Participant flow — Overall Study
MilestoneEntire Study Population
Started61
Completed51
Not completed10
Withdrew: Adverse event6
Withdrew: Withdrawal by subject2
Withdrew: Violation of eligibility criteria1
Withdrew: Change of therapy1

Outcome measures

PrimaryPercentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care

Photo-based evaluation by independent experts blinded to the treatment regime.

Time frame:
2 to 3 weeks
Reported as:
Number · percentage of patients
Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care
percentage of patientsEntire Study Population
Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care85.7 (69.7 to 95.2)
Statistical analysis
  • Entire Study Population · Binomial test · p = <0.0001 (1-sided, significance level = 0.025)
SecondaryIntra-individual Difference in Time to Wound Closure Between Wound Halves, Either Treated With Oleogel-S10 or Treated With Standard of Care
Time frame:
2 to 3 weeks

Results for this outcome have not been posted.

SecondaryTime From Study Start After Burn Accident Until Wound Closure is Achieved Separately for Wound Halves Treated With Oleogel-S10 vs. Standard of Care
Time frame:
2 to 3 weeks

Results for this outcome have not been posted.

SecondaryPercentage of Patients With Wound Closure at Different Time Points
Time frame:
2 to 3 weeks

Results for this outcome have not been posted.

SecondaryPercentage of Wound Epithelialization at Different Time Points as Assessed by the Investigator
Time frame:
2 to 3 weeks

Results for this outcome have not been posted.

SecondaryLikert Scale Rating of Efficacy (Evaluated by Both the Investigators and Patients)

By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to grade the efficacy of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale

Time frame:
2 to 3 weeks

Results for this outcome have not been posted.

SecondaryCosmetic Outcome After 3 and 12 Months After Burn Accident, in Relation to Texture, Redness, Growth of Hair and Pigmentation, Based on Blinded Photo Evaluation
Time frame:
3 and 12 months

Results for this outcome have not been posted.

SecondaryLikert Scale Rating of Tolerance (Evaluated by Both the Investigators and Patients)

By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to provide their opinion on the tolerance of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale

Time frame:
2 to 3 weeks

Results for this outcome have not been posted.

SecondaryPK Data: Systemic Presence/Concentration of Betulin in Blood Plasma Samples
Time frame:
2 to 3 weeks

Results for this outcome have not been posted.

SecondaryMicrobial Colonization of the Wound Halves
Time frame:
2 to 3 weeks

Results for this outcome have not been posted.

SecondaryAssessment of Adverse Events
Time frame:
2 to 3 weeks

Results for this outcome have not been posted.

Adverse events

Collected over Day 0 (start of treatment) till end of treatment (Day 21 or earlier if full wound closure was achieved earlier, or later, if the investigator decided to change medication and/or treatment due to unsatisfying wound closure after Day 21).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Entire Study Population - Systemic AEs—2/61 (3.3%)0/61 (0%)
Oleogel-S10 Localized AE—1/61 (1.6%)0/61 (0%)
Octenilin Localized AE—1/61 (1.6%)0/61 (0%)
Localized AE Both Wound Halves—4/61 (6.6%)0/61 (0%)
Most frequent serious events
Most frequent serious events
EventEntire Study Population - Systemic AEsOleogel-S10 Localized AEOctenilin Localized AELocalized AE Both Wound Halves
Condition aggravatedGeneral disorders0/610/610/612/61
Wound infectionInfections and infestations0/610/610/612/61
Wound necrosisInjury, poisoning and procedural complications0/611/610/610/61
Tonsil cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/610/610/610/61
PyrexiaGeneral disorders1/610/610/610/61
Soft tissue infectionInfections and infestations0/610/611/610/61

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Entire Study Population
<=18 years1
Between 18 and 65 years54
>=65 years6
Age, Continuous
Age, Continuous(years)Entire Study Population
Median41 (18 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female19
Male42
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
Sweden3
United Kingdom28
Switzerland4
Germany26
08

Study locations

9 sites
  • Unfallkrankenhaus Berlin
    Berlin, Germany
  • Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil
    Bochum, Germany
  • Universitätsklinikum Schleswig-Holstein
    Lübeck, Germany
  • Linköping University Hospital
    Linköping, Sweden
  • University Hospital
    Uppsala, Sweden
  • Centre Hospitalier Universitaire Vaudois
    Lausanne, Switzerland
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, United Kingdom
  • Broomfield Hospital
    Chelmsford, United Kingdom
  • Queen Victoria Hospital
    East Grinstead, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Jul 2013 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2012
First posted
Aug 6, 2012
Start
Aug 2012
Primary completionActual
Jul 2013
CompletionActual
Jul 2014
Results first posted
Sep 28, 2015
Last update
Sep 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01657292
Lead sponsor
Birken AG
Responsible party
Sponsor
First posted
Aug 6, 2012
Start date
Aug 2012
Primary completion
Jul 2013
Completion
Jul 2014
Results posted
Sep 28, 2015
Last update
Sep 28, 2015

Study contacts

Bernd Hartmann, Dr.
principal investigator · Trauma Hospital Berlin, Warener Str. 7, 12683 Berlin, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Episalvan · Birch triterpenes

Start the discussion